Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGX-104 in advanced solid malignancies
NCT02922764Phase 1Completed
- Sponsor
- Inspirna
- Start
- Nov 2016
- Primary completion
- Jan 2025
- Modality
- Prophylactic Vaccines, Small Molecules, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of abequolixron in solid tumor, lymphoma, non-small cell lung cancer (NSCLC) and 4 more (5 arms), sponsored by Inspirna. Primary endpoints: Maximum Tolerated Dose at 6 months, Overall Response Rate at 24 months and 2 more. Started Nov 2016; status: completed.
02
Drugs
abequolixron
03
Conditions
solid tumorlymphomanon-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT02922764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02922764.